12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Company News  |  Other News

Bayer, Natco cancer, generics news

India's Intellectual Property Appellate Board (IPAB) rejected a petition from Bayer seeking a stay of an order granting Natco a compulsory license in India to manufacture and market a generic version of Bayer's kidney and liver cancer drug Nexavar sorafenib. In March, the Indian Patent Office granted the compulsory license for Nexavar because Bayer did not make the drug available to the public at a "reasonably affordable price." The license allows Natco to sell sorafenib in India at a price not exceeding Rs8,880 ($164) for a month's supply of 120...

Read the full 437 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >